Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
Mirabegron (MBR) is a β<sub>3</sub>-adrenoceptor agonist used for treating overactive bladder syndrome. Due to its poor solubility and low bioavailability (<i>F</i>), the development of novel MBR formulations has garnered increasing attention. Recently, co-amorphous dispersions of MBR, such as MBR-1...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
MDPI AG
2023-09-01
|
| Rangatū: | Pharmaceutics |
| Ngā marau: | |
| Urunga tuihono: | https://www.mdpi.com/1999-4923/15/9/2277 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|